Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL

“Looking at the outcome data and the entire overall survival [OS] for the TRANSFORM [trial] and the long-term follow-up cohort, the median OS was not reached, with a 48-month OS [rate] of [61.5]% in the liso-cel–treated patients.”

Manali Kamdar, MD, an associate professor of medicine-hematology in the Division of Hematology at the University of Colorado and clinical director of Lymphoma Services at the UCHealth Blood Disorders and Cell Therapies Center—Anschutz Medical Campus and the University of Colorado Cancer Center, discussed long-term follow-up findings from the phase 3 TRANSFORM trial (NCT03575351) investigating lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with second-line relapsed/refractory large B-cell lymphoma.